Sickle Cell Anemia Genetic Analysis
Sickle cell disease (SCD) is an autosomal recessive inherited disease associated with mutations in the Beta globin (HBB gene) located on chromosome 11. The mutations result in a variant HBB called sickle hemoglobin (Hb S). The presence of Hb S results in abnormal red blood cells that appear sickle-shaped (crescent shaped). This morphology makes the sickle cells difficult to pass through small blood vessels. If the blood cells cannot reach parts of the body due to blockage, the deprived tissues become ischemic and tissues become damaged. To express SCD an individual must possess either two copies of Hb S or one copy of Hb S coupled with the presence of another HBB variant.
Individuals with SCD have a high morbidity and mortality rate due to intermittent vaso-occlusive events and chronic hemolytic anemia. Symptoms of SCD include stroke, chronic anemia, splenic and renal infarcts with resultant dysfunction, hemearthrosis, and susceptibility to bacterial infections. Pediatric mortality is primarily due to bacterial infections and stroke. In the United States, 1 in every 600 African-Americans has sickle cell anemia. Carrier frequency (presence of a single variant allele) is 8-10% in African-Americans and is common in individuals of sub-Saharan African, Mediterranean, Caribbean, Arabian, South and Central American, and East Indian descent.
Over 475 p-globin gene variants exist, and several result in life-threatening illness. Most common mutation that is associated with life threatening illness are: c.19G>A (HbC), c.20A>T (HbS), c.79G>A (HbE). Molecular genetic testing mutation analysis will usually test for all four mutations (c.19G>A, c.20A>T, c.79G>A). Detection of any of these mutations that result in the single amino acid changes resulting in hemoglobin S, hemoglobin C, hemoglobin D will result in hemoglobin variants associated with SCD. DNA sequencing is used to detect larger number of mutations (extensive mutation analysis), when mores diagnostic study is needed.
- Confirmation of sickle cell disease diagnosis
- Prenatal testing for sickle cell disease
- Carrier testing for sickle cell trait
- Differentiation of other sickling hemoglobins (e.g., Hemoglobin C-Harlem) from Hemoglobin S
Mutation not detected (Negative for mutation analyzed)
Polymerase Chain Reaction (PCR) and Amplified Refractory Mutation System (ARMS), PCR and DNA sequence analysis, PCR and Allele Specific Primer Extension (ASPE), next generation sequencing (NGS).
Whole Blood EDTA.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
1-2 weeks.
- Clin Perinatol. 2001 Jun;28(2):435-48. [PMID: 11499064]
- Am J Epidemiol. 2000 May 1;151(9):839-45. Review. [PMID: 10791557]
- Am J Clin Pathol. 1989 Sep;92(3):347-51. [PMID: 2773852]
- Semin Perinatol. 2010 Apr;34(2):134-44. [PMID: 20207263]
- N Engl J Med. 1997 Sep 11;337(11):762-9. [PMID: 9287233]
- Am J Epidemiol. 2000 May 1;151(9):839-45. [PMID: 10791557]
- N Engl J Med. 1999 Apr 1;340(13):1021-30. [PMID: 10099145]
- J Med Screen. 2001;8(1):8-14. [PMID: 11373853]